'Alk inhibitor' presentation slideshows

Targeted Therapy for Metastatic NSCLC

Targeted Therapy for Metastatic NSCLC. Gregory J. Riely October 14, 2012. Disclosures. Consulting Chugai Ariad Tragara Daiichi Novartis Abbott Foundation Medicine Celgene. Research Funding Novartis Chugai Glaxo SmithKline BMS Infinity Pfizer Merck. Lung Adenocarcinomas.

868 views • 68 slides

Figure 2 Timeline depicting the milestones leading to the clinical testing of the ALK inhibitor crizotinib targeting the full-length ALK in neuroblastoma (above) and translocated ALK in non-small-cell lung cancer (below) .

356 views • 1 slides